750 17th St. NW, Suite 1100
57 articles with REGENXBIO
Program aims to develop a one-time treatment to halt progression of this rare, pediatric, neurodegenerative disease
Maryland-based REGENXBIO is expanding its gene therapy pipeline to include a new treatment for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease.
REGENXBIO Announces Closing of Public Offering of 2,700,000 Shares of Its Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
REGENXBIO Inc. announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price to the public of $65.00 per share
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the pricing of an underwritten public offering of 2,700,000 shares of its common stock at the price of $65.00 per share before underwriting discounts and commissions.
REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemia
Announces positive interim update from RGX-314 Phase I clinical trial for wet AMD
REGENXBIO Inc. announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering.
REGENXBIO to Host Conference Call and Webcast on August 8 to Discuss Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials
REGENXBIO Inc. announced that its previously announced conference call and webcast on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its financial results for the quarter ended June 30, 2018
REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2018 Financial Results and Recent Operational Highlights
REGENXBIO Inc. announced that it will host a conference call on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its financial results for the quarter ended June 30, 2018 and recent operational highlights.
REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I
REGENXBIO Inc. (Nasdaq: RGNX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-111. RGX-11.
6/12/2018Regenxbio snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier this year.
REGENXBIO Receives $100 Million Accelerated License Payment Due to Acquisition of AveXis by Novartis
REGENXBIO Inc. announced that it has received an accelerated license payment of $100 million under its license agreement (the License Agreement) with AveXis, Inc.
S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500 and S&P SmallCap 600 effective prior to the open of trading on Thursday, June 7
REGENXBIO Inc. announced the appointment of Alexandra Glucksmann, Ph.D., to its board of directors, effective as of May 25, 2018.
The company recognizes International MPS Awareness Day 2018 on May 15 and supports the 5th Annual Million Dollar Bike Ride for rare disease research
REGENXBIO Receives FDA Fast Track Designation for RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II
REGENXBIO Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-121.
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2018 Financial Results and Recent Operational Highlights
REGENXBIO Inc. announced that it will host a conference call on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2018 and recent operational highlights.
Gene therapy treatment is a high risk, high reward venture, but the promises of a therapy developed through these programs could be life-changing for patients.
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
AveXis’ initial proprietary gene therapy candidate, AVXS-101, is in a pivotal trial for the treatment of SMA Type 1, and a Phase 1 trial for SMA Type 2. AVXS-101 uses REGENXBIO’s NAV AAV9 vector.
The company ended 2017 with greater than $175 million in cash, cash equivalents and marketable securities.
REGENXBIO Announces IND Active for Phase I/II Trial of RGX-121 to Treat Mucopolysaccharidosis Type II
RGX-121 has received orphan drug designation as well as rare pediatric disease designation from the FDA.